Dr. Barry Byrne Presents Improvements in Key Duchenne Muscular Dystrophy Measures, Microdystrophin Expression
Data from a recent interim analysis of the open-label phase 1/2 IGNITE-DMD (NCT03368742) suggest that intravenous SGT-001 (Solid Biosciences) is well-tolerated and efficacious in Duchenne muscular dystrophy (DMD).
These findings were presented virtually by principal investigator Barry Byrne, MD, Ph.D., a professor and associate chair at UF Health pediatric research, at the Muscular Dystrophy Association’s (MDA) Scientific and Clinical Conference, March 15-18, 2021.
“Boys with Duchenne rarely run, and so it’s been very rewarding to hear from families, [about] these newfound abilities to run and other skills have led to the ability to participate in sports or even ride a bike. These moments are a really important part of childhood, so I’ve been very gratified to share these moments with the families,” Byrne said during his presentation.
Learn more about Dr. Barry Byrne Presents Improvements in Key Duchenne Muscular Dystrophy Measures, Microdystrophin Expression.